Alzheimer's Challenge 2012: seeking new tools to help improve Alzheimer's care
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program (AIP), Janssen Alzheimer Immunotherapy, and the Geoffrey Beene Gives Back® Alzheimer's Initiative introduced the Alzheimer's Challenge 2012 at the Care Innovations Summit in Washington, D.C.
Bristol-Myers Squibb delivers solid fourth quarter capping a year highlighted by new product approvals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced solid financial results for the fourth quarter of 2011. This concludes a year in which the Company received important new product approvals for YERVOY® and NULOJIX® in both the U.S. and Europe, and ELIQUIS® in Europe for the prevention of venous thromboembolic events.
Amgen to Acquire Micromet
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.
Novartis delivers strong underlying financial performance in 2011
- Details
- Category: Novartis
Novartis' net sales rose 4% (+5% cc) to USD 14.8 billion in the fourth quarter. The strengthening of the US dollar against most major currencies negatively impacted sales by 1 percentage point.
Abbott reports double-digit ongoing earnings-per-share growth in fourth quarter and full-year 2011
- Details
- Category: Abbott
Abbott's worldwide sales increased 4.1 percent to $10.4 billion, including a favorable 0.2 percent effect of foreign exchange. Emerging markets sales were $2.5 billion, representing nearly 25 percent of total sales, with particularly strong growth in Nutritionals, Vascular and Diagnostics.
Novo Nordisk establishes type 1 diabetes R&D center in Seattle
- Details
- Category: Novo Nordisk
Novo Nordisk will establish a type 1 diabetes R&D center in Seattle, US. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.
Roche supports cancer care development program in Ethiopia
- Details
- Category: Roche
Roche announced a grant to the Albert Einstein College of Medicine of Yeshiva University in New York City, which will be used for the establishment of a program to improve basic cancer care in Ethiopia. The grant funding comes from the Roche African Research Foundation.
More Pharma News ...
- Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
- Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients
- Novartis receives approval for Lucentis® and launches Galvus® in China
- Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
- Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners launched Warp Drive Bio
- Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon
- Novartis to restructure US business to strengthen competitive position